PMCB
Price
$1.00
Change
-$0.03 (-2.91%)
Updated
Jul 21, 04:57 PM (EDT)
Capitalization
7.07M
35 days until earnings call
XBIT
Price
$2.94
Change
-$0.04 (-1.34%)
Updated
Jul 21, 04:59 PM (EDT)
Capitalization
90.85M
25 days until earnings call
Interact to see
Advertisement

PMCB vs XBIT

Header iconPMCB vs XBIT Comparison
Open Charts PMCB vs XBITBanner chart's image
PharmaCyte Biotech
Price$1.00
Change-$0.03 (-2.91%)
Volume$400
Capitalization7.07M
XBiotech
Price$2.94
Change-$0.04 (-1.34%)
Volume$400
Capitalization90.85M
PMCB vs XBIT Comparison Chart in %
Loading...
PMCB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XBIT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
PMCB vs. XBIT commentary
Jul 22, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PMCB is a Hold and XBIT is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 22, 2025
Stock price -- (PMCB: $1.03 vs. XBIT: $2.98)
Brand notoriety: PMCB and XBIT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PMCB: 275% vs. XBIT: 99%
Market capitalization -- PMCB: $7.07M vs. XBIT: $90.85M
PMCB [@Biotechnology] is valued at $7.07M. XBIT’s [@Biotechnology] market capitalization is $90.85M. The market cap for tickers in the [@Biotechnology] industry ranges from $286.69B to $0. The average market capitalization across the [@Biotechnology] industry is $2.44B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PMCB’s FA Score shows that 1 FA rating(s) are green whileXBIT’s FA Score has 1 green FA rating(s).

  • PMCB’s FA Score: 1 green, 4 red.
  • XBIT’s FA Score: 1 green, 4 red.
According to our system of comparison, PMCB is a better buy in the long-term than XBIT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PMCB’s TA Score shows that 3 TA indicator(s) are bullish while XBIT’s TA Score has 4 bullish TA indicator(s).

  • PMCB’s TA Score: 3 bullish, 6 bearish.
  • XBIT’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, XBIT is a better buy in the short-term than PMCB.

Price Growth

PMCB (@Biotechnology) experienced а -4.63% price change this week, while XBIT (@Biotechnology) price change was +5.30% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.21%. For the same industry, the average monthly price growth was +15.57%, and the average quarterly price growth was +33.92%.

Reported Earning Dates

PMCB is expected to report earnings on Aug 25, 2025.

XBIT is expected to report earnings on Aug 15, 2025.

Industries' Descriptions

@Biotechnology (+2.21% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
XBIT($90.9M) has a higher market cap than PMCB($7.07M). XBIT YTD gains are higher at: -24.557 vs. PMCB (-34.395). PMCB has higher annual earnings (EBITDA): -4.5M vs. XBIT (-36.99M). XBIT has more cash in the bank: 156M vs. PMCB (16.8M). PMCB has less debt than XBIT: PMCB (75.2K) vs XBIT (10.2M). PMCB (0) and XBIT (0) have equivalent revenues.
PMCBXBITPMCB / XBIT
Capitalization7.07M90.9M8%
EBITDA-4.5M-36.99M12%
Gain YTD-34.395-24.557140%
P/E Ratio0.77N/A-
Revenue00-
Total Cash16.8M156M11%
Total Debt75.2K10.2M1%
FUNDAMENTALS RATINGS
PMCB vs XBIT: Fundamental Ratings
PMCB
XBIT
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
10
Undervalued
73
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
3594
PRICE GROWTH RATING
1..100
8761
P/E GROWTH RATING
1..100
986
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PMCB's Valuation (10) in the null industry is somewhat better than the same rating for XBIT (73) in the Biotechnology industry. This means that PMCB’s stock grew somewhat faster than XBIT’s over the last 12 months.

PMCB's Profit vs Risk Rating (100) in the null industry is in the same range as XBIT (100) in the Biotechnology industry. This means that PMCB’s stock grew similarly to XBIT’s over the last 12 months.

PMCB's SMR Rating (35) in the null industry is somewhat better than the same rating for XBIT (94) in the Biotechnology industry. This means that PMCB’s stock grew somewhat faster than XBIT’s over the last 12 months.

XBIT's Price Growth Rating (61) in the Biotechnology industry is in the same range as PMCB (87) in the null industry. This means that XBIT’s stock grew similarly to PMCB’s over the last 12 months.

XBIT's P/E Growth Rating (6) in the Biotechnology industry is significantly better than the same rating for PMCB (98) in the null industry. This means that XBIT’s stock grew significantly faster than PMCB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PMCBXBIT
RSI
ODDS (%)
N/A
Bearish Trend 4 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
81%
Bullish Trend 4 days ago
69%
Momentum
ODDS (%)
Bearish Trend 4 days ago
88%
Bearish Trend 4 days ago
87%
MACD
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
85%
Bullish Trend 4 days ago
68%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
70%
Bullish Trend 4 days ago
72%
Advances
ODDS (%)
Bullish Trend 6 days ago
75%
Bullish Trend 5 days ago
67%
Declines
ODDS (%)
Bearish Trend 11 days ago
88%
Bearish Trend 11 days ago
84%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
74%
Bearish Trend 4 days ago
89%
Aroon
ODDS (%)
Bearish Trend 4 days ago
88%
Bearish Trend 4 days ago
86%
View a ticker or compare two or three
Interact to see
Advertisement
PMCB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XBIT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
BEN24.600.08
+0.33%
Franklin Resources
SEPN12.55-0.07
-0.55%
Septerna Inc
AIMD2.77-0.03
-1.07%
AINOS Inc
EVTC33.28-0.43
-1.28%
EVERTEC
LARK26.25-0.40
-1.50%
Landmark Bancorp

PMCB and

Correlation & Price change

A.I.dvisor tells us that PMCB and CRBP have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that PMCB and CRBP's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PMCB
1D Price
Change %
PMCB100%
+0.98%
CRBP - PMCB
31%
Poorly correlated
-0.23%
APLS - PMCB
25%
Poorly correlated
-2.84%
XBIT - PMCB
24%
Poorly correlated
-0.67%
FBIO - PMCB
22%
Poorly correlated
+1.04%
SER - PMCB
22%
Poorly correlated
+0.94%
More

XBIT and

Correlation & Price change

A.I.dvisor indicates that over the last year, XBIT has been loosely correlated with GBIO. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if XBIT jumps, then GBIO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XBIT
1D Price
Change %
XBIT100%
-0.67%
GBIO - XBIT
43%
Loosely correlated
-22.08%
GLSI - XBIT
41%
Loosely correlated
-5.77%
OBIO - XBIT
40%
Loosely correlated
N/A
NAUT - XBIT
40%
Loosely correlated
-1.33%
TECH - XBIT
40%
Loosely correlated
-2.38%
More